Compare Eversource Energy (D/B/A) Common Stock (ES) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eversource Energy (D/B/A) Common Stock vs Incyte Corporation — how do they compare? Eversource Energy (D/B/A) Common Stock trades at $66.67 (market cap $24.77B), while Incyte Corporation trades at $112.82 (market cap $22.01B). The key difference: Eversource Energy (D/B/A) Common Stock and Incyte Corporation are close in size by market cap, and Eversource Energy (D/B/A) Common Stock pays a 4.79% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eversource Energy (D/B/A) Common Stock for 0 Days and Incyte Corporation for 33 Days on average.
| ES | INCY | |
|---|---|---|
Market Cap | $24.77B | $22.01B |
Volume | 3,738,127 | 2,589,484 |
Sector | Utilities | Health |
52-Week High | $76.21 | $129.93 |
52-Week Low | $63.28 | $86.17 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $54.84B | $17.52B |
Dividend Yield | 4.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eversource Energy (ES) trades at $65.75, down 0.53% with neutral technical signals. The company maintains solid fundamentals with a 17.08 P/E ratio, 84.95% gross margin, and recent earnings beats in Q4 2025 and Q1 2026. Analyst consensus targets $73.75 with 31% buy ratings, while the company progresses on grid modernization projects and regulatory clarity in Connecticut.
ES offers steady utility exposure with 4.5% dividend yield and $26.5B capex plan supporting growth, though Q2 2026 earnings miss and regulatory uncertainty pose near-term risks. The stock presents value for income investors seeking regulated utility stability with infrastructure upside potential.
Incyte (INCY) trades at $111.57, up 0.19% on the day, with a bearish technical signal but strong fundamentals. Recent earnings beats in Q1 and Q2 2026, with EPS of $1.81 and $3.09 respectively, highlight robust profitability. The company's net income margin improved to 27.71% in 2025, and revenue growth is projected to reach $5.8 billion in 2026. Key developments include FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting long-term growth beyond JAKAFI exclusivity post-2029.
The outlook for INCY is positive, driven by pipeline advancements and a $4 billion sales target for non-JAKAFI products. However, risks include reliance on JAKAFI until 2029 and competitive pressures. Analysts maintain a buy consensus with a $132.43 price target, suggesting ~19% upside. Investors should weigh strong cash flow and valuation metrics against execution risks in pipeline commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Eversource Energy (D/B/A) Common Stock
Eversource Energy is a regulated utility holding company delivering electricity, natural gas, and water to customers in Connecticut, Massachusetts, and New Hampshire. It operates through electric distribution and transmission, natural gas distribution, and water distribution segments, via subsidiaries including CL&P, NSTAR, PSNH, Yankee Gas, and Aquarion.
Read more on ES →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
